PL3363811T3 - Sposób wytwarzania białka fuzyjnego z domeną fc igg - Google Patents

Sposób wytwarzania białka fuzyjnego z domeną fc igg

Info

Publication number
PL3363811T3
PL3363811T3 PL16855776.7T PL16855776T PL3363811T3 PL 3363811 T3 PL3363811 T3 PL 3363811T3 PL 16855776 T PL16855776 T PL 16855776T PL 3363811 T3 PL3363811 T3 PL 3363811T3
Authority
PL
Poland
Prior art keywords
igg
domain
fusion protein
producing fusion
producing
Prior art date
Application number
PL16855776.7T
Other languages
English (en)
Inventor
Soon Jae Park
Hye Shin Chung
Sun Ah You
Jeong Soo CHO
Original Assignee
Alteogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58703642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3363811(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen, Inc. filed Critical Alteogen, Inc.
Priority claimed from PCT/KR2016/011561 external-priority patent/WO2017065559A1/ko
Publication of PL3363811T3 publication Critical patent/PL3363811T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
PL16855776.7T 2015-10-15 2016-10-14 Sposób wytwarzania białka fuzyjnego z domeną fc igg PL3363811T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150144330 2015-10-15
KR1020160132633A KR101936049B1 (ko) 2015-10-15 2016-10-13 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
PCT/KR2016/011561 WO2017065559A1 (ko) 2015-10-15 2016-10-14 Igg fc 도메인을 가지는 융합 단백질의 생산방법

Publications (1)

Publication Number Publication Date
PL3363811T3 true PL3363811T3 (pl) 2023-07-17

Family

ID=58703642

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16855776.7T PL3363811T3 (pl) 2015-10-15 2016-10-14 Sposób wytwarzania białka fuzyjnego z domeną fc igg

Country Status (12)

Country Link
US (2) US11414476B2 (pl)
EP (2) EP4098659A1 (pl)
JP (2) JP6783305B2 (pl)
KR (1) KR101936049B1 (pl)
CN (2) CN108137672B (pl)
AU (1) AU2016339642B2 (pl)
BR (1) BR112018007590A2 (pl)
CA (1) CA3001977C (pl)
ES (1) ES2945537T3 (pl)
MX (1) MX2018004580A (pl)
PL (1) PL3363811T3 (pl)
RU (1) RU2732237C2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
CN115197961B (zh) * 2022-06-20 2024-04-16 岭南现代农业科学与技术广东省实验室肇庆分中心 一种非洲猪瘟病毒b602l重组蛋白稳定表达细胞系及其构建方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
ATE293164T1 (de) * 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CA2760687A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
RU2577972C2 (ru) * 2010-04-26 2016-03-20 Новартис Аг Способ получения рекомбинантного полипептида
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
EP2879694A1 (en) 2012-08-02 2015-06-10 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JP6689189B2 (ja) 2013-03-26 2020-04-28 コヒラス・バイオサイエンシズ・インコーポレイテッド タンパク質産生方法
EP2987276B1 (en) 2013-04-15 2019-02-27 Telefonaktiebolaget LM Ericsson (publ) Signaling of system information to mtc-devices
CN103319610B (zh) 2013-07-05 2016-01-27 华博生物医药技术(上海)有限公司 重组融合蛋白及其制法和用途
WO2015116315A1 (en) 2014-01-29 2015-08-06 Amgen Inc. Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
CN104974262B (zh) * 2014-04-04 2019-08-09 华博生物医药技术(上海)有限公司 重组双功能融合蛋白及其制法和用途
WO2015186075A1 (en) * 2014-06-03 2015-12-10 Lupin Limited Cell culture process for producing a protein
KR20160132633A (ko) 2015-05-11 2016-11-21 주식회사 엘지화학 배터리 시스템 및 그 연결 제어 방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基

Also Published As

Publication number Publication date
RU2018117705A3 (pl) 2019-11-15
JP2020114266A (ja) 2020-07-30
US20220348636A1 (en) 2022-11-03
US20180298078A1 (en) 2018-10-18
JP6783305B2 (ja) 2020-11-11
EP3363811A4 (en) 2019-03-13
AU2016339642A1 (en) 2018-04-12
US11414476B2 (en) 2022-08-16
BR112018007590A2 (pt) 2018-10-23
CN108137672A (zh) 2018-06-08
KR20170044594A (ko) 2017-04-25
ES2945537T3 (es) 2023-07-04
RU2732237C2 (ru) 2020-09-14
KR101936049B1 (ko) 2019-01-08
CN115247196A (zh) 2022-10-28
EP4098659A1 (en) 2022-12-07
CN108137672B (zh) 2022-09-06
CA3001977C (en) 2023-06-20
JP2018530344A (ja) 2018-10-18
MX2018004580A (es) 2018-09-19
AU2016339642B2 (en) 2019-07-25
EP3363811B1 (en) 2023-04-19
RU2018117705A (ru) 2019-11-15
EP3363811A1 (en) 2018-08-22
CA3001977A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
HK1244019A1 (zh) 融合蛋白
EP3505538A4 (en) PROCESS FOR PRODUCING ANTIBODY FUSION PROTEIN
EP3188758A4 (en) Sirp alpha-antibody fusion proteins
GB201509413D0 (en) Fusion protein
EP3223730A4 (en) Method and apparatus for joint fusion
HK1232136A1 (zh) 融合蛋白
HK1258125A1 (zh) 胰島素免疫球蛋白融合蛋白
EP3118210A4 (en) Method for purifying immunoglobulin
PL3363811T3 (pl) Sposób wytwarzania białka fuzyjnego z domeną fc igg
EP3118209A4 (en) Method for purifying immunoglobulin
GB201504691D0 (en) Fusion protein
EP3438262A4 (en) PROCESS FOR PRODUCTION OF PROTEIN
EP3495491A4 (en) PROCESS FOR PRODUCING RECOMBINANT PROTEIN
EP3382031A4 (en) METHOD FOR THE PRODUCTION OF FIBROINARY PROTEIN
EP3092002A4 (en) Method of purifying monoclonal antibodies
IL258981A (en) Methods for the production of proteins
HK1257937A1 (zh) 融合蛋白
EP3147368A4 (en) Method for producing fibroin-like protein
EP3213862A4 (en) Laser-welded joint and method for producing same
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB201602850D0 (en) Fusion proteins
IL250263A0 (en) An improved process for the preparation of immunoglobulin g (igg)
EP3170901A4 (en) Method for identifying epitope of protein
IL244857A0 (en) A fusion protein of acetylcholinesterase and the fc region